Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer.
Saved in:
| Title: | Interplay between malic enzyme 2, de novo serine synthesis, and the malate-aspartate shuttle drives metabolic adaptation in triple-negative breast cancer. |
|---|---|
| Authors: | Jeon JH; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States.; Department of Biomedical Engineering, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Laboratory for Systems Biology of Human Diseases, University of Michigan, MI, 48109, Ann Arbor, United States.; Biointerfaces Institute, University of Michigan, MI, 48109, Ann Arbor, United States., Slayton MD; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States., Krinkel B; School of Biological Sciences, University of Auckland, Auckland, New Zealand., Animasahun O; Department of Biomedical Engineering, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA., Shankaran A; Department of Biomedical Engineering, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA., Wuchu F; Department of Biomedical Engineering, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA., Nenwani M; Department of Biomedical Engineering, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA., Farah Z; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States., Burke J; School of Biological Sciences, University of Auckland, Auckland, New Zealand., Achreja A; Department of Biomedical Engineering, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA., Nilaj B; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States., Kohagen K; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States., Eu YH; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States., Rosenfeld A; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States., Collard M; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States., Bao L; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States., Cheng X; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States., Kleer C; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States., Squire C; School of Biological Sciences, University of Auckland, Auckland, New Zealand., Loomes K; School of Biological Sciences, University of Auckland, Auckland, New Zealand., Nagrath D; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States. dnagrath@umich.edu.; Department of Biomedical Engineering, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA. dnagrath@umich.edu.; Department of Chemical Engineering, University of Michigan, MI, 48109, Ann Arbor, United States. dnagrath@umich.edu.; Laboratory for Systems Biology of Human Diseases, University of Michigan, MI, 48109, Ann Arbor, United States. dnagrath@umich.edu.; Biointerfaces Institute, University of Michigan, MI, 48109, Ann Arbor, United States. dnagrath@umich.edu., Merajver SD; Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, 48109, USA. smerajve@med.umich.edu.; Rogel Cancer Center, Michigan Medicine, University of Michigan, MI, 48109, Ann Arbor, United States. smerajve@med.umich.edu. |
| Source: | Cancer & metabolism [Cancer Metab] 2025 Oct 14; Vol. 13 (1), pp. 42. Date of Electronic Publication: 2025 Oct 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: BioMed Central Country of Publication: England NLM ID: 101607582 Publication Model: Electronic Cited Medium: Print ISSN: 2049-3002 (Print) Linking ISSN: 20493002 NLM ISO Abbreviation: Cancer Metab Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2049-3002 |
|---|---|
| DOI: | 10.1186/s40170-025-00410-5 |
